Supernatants from lymphocytes stimulated with Bacillus Calmette-Guerin can modify the antigenicity of tumours and stimulate allogeneic T-cell responses by Liu, WM et al.
Supernatants from lymphocytes stimulated with Bacillus
Calmette-Guerin can modify the antigenicity of tumours
and stimulate allogeneic T-cell responses
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BACKGROUND: Reduced expression of class 1 human leucocyte antigens (HLA1) is often a mechanism by which tumours evade
surveillance by the host immune system. This is often associated with an immune function that is unable to mount appropriate
responses against disease, which can result in a state that favours carcinogenesis.
METHODS: In the current study, we have explored the effects of Bacillus Calmette-Guerin (BCG) on the cytokine output of leucocytes,
which is a key determinant in generating antitumour action, and have also assessed the effect of these cytokine cocktails on HLA1
expression in solid tumour cell lines.
RESULTS: BCG potently activated a broad range of leucocytes, and also enhanced the production of cytokines that were
Th1-predominant. Supernatants from BCG-treated leucocytes significantly increased the expression of HLA1 on the surface of cancer
cell lines, which correlated with increased cytolytic T-cell activity. We also showed that the increased HLA1 expression was
associated with activation of intracellular signalling pathways, which was triggered by the increases in the Th1-cytokines interferon-g
and tumour necrosis factor-a, as counteracting their effects negated the enhancement.
CONCLUSION: These studies reaffirm the role of BCG as a putative immunotherapy through their cytokine-modifying effects on
leucocytes and their capacity to enhance tumour visibility.
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It has been known for sometime that tumours possess antigens,
which can be targeted by intrinsic immune processes as part of
disease clearance. These tumour-associated antigens can be
presented in complex with the human leucocyte antigen (HLA)-1
on their surface, which can evoke cytolytic immune responses
(Yang and Yi, 2010). The principle of enhancing cell killing
underscores immunotherapy for a variety of neoplasia. However,
successful incorporations into clinical treatment strategies of
approaches that exploit this effect have been limited (Copier et al,
2011). These have been due, in part, to deficiencies in the response
of the immune system to tumour that have many causes; reasons
have included (i) reduced immunovisibility of tumours, (ii)
desensitised/anergic immune system and (iii) inappropriate
immune reaction to tumours.
Specific immunity is broadly categorised as being cell-mediated
or humoral, the initiation of which determines the suitability of the
immune response. They can be distinguished by the types of
cytokines produced by CD4þ T-cells, as cell-mediated immunity
is often defined by the presence of T-cells producing Th1 cytokines
such as interleukin (IL)2, interferon (IFN)-g and tumour necrosis
factor (TNF)-a; while humoral immunity has a profile rich in Th2
cytokines such as IL4, IL6 and IL10 (Abbas et al, 1996). These
cytokines have divergent functions, and determine the nature of
the response. Generally, a Th1-dominant response is more effective
against intracellular pathogens, while a Th2-response is directed
more towards external stimuli. It is important that the proper type
of immunity is triggered to ensure an effective response. Indeed, a
Th1-response would favour the potentiation of a CD8þ T-cell
cytotoxic response against tumour (Dunn et al, 2002), whereas a
Th2-response would antagonise this effect. Furthermore, a Th2-
dominant profile is often seen in cancer patients that may favour
tumour growth (Ellyard et al, 2007).
Treatment strategies that include systemic immune stimulation
in its armoury would be powerful tools against cancer; and indeed,
our group has focused on developing immunotherapies that follow
such a course. Of particular interest has been our work with
mycobacteria (Hrouda et al, 1998; Maraveyas et al, 1999;
Nicholson et al, 2003). Stimulating an immune response using
mycobacterium preparations such as Bacillus Calmette-Guerin
(BCG) and Mycobacterium vaccae can enhance the cytotoxic
response directed against some tumours. Furthermore, the
mechanism of BCG may be mediated by Th1 cytokines (Orme
et al, 1993), which evoke potent cell-mediated immune reactions
against diseases. Apart from this effect, modifications to cytokine
production by T-cells and other peripheral-blood mononuclear
cells (PBMCs) may have other effects. For example, we have
previously shown that some chemotherapies possess immune-
modulatory character (Liu et al, 2010, 2011). This is manifest as an
ability to upregulate HLA1 expression on tumours directly. As
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HLA1 expression on tumour cells can be induced by stimulation
with type I interferons (Seliger et al, 2008), the effects that BCG
had on cytokine production could provide a way that it could
modify tumours to make them more antigenic. As cytotoxic T-cells
are restricted by HLA1 and kill tumour cells expressive of them,
the restoration of HLA1 expression could reinitialise immune
visibility to these tumour cells and lead to an enhanced immuno-
cytolytic response.
Consequently, as part of our ongoing research activities, we have
worked on the hypothesis that BCG alters the cytokines produced
by PBMCs that leads to a greater antigenicity of tumour cells and
thus an enhanced cytotoxic immune response. Supplementary to
this, we have also explored the role that signalling pathways have
on this process.
MATERIALS AND METHODS
Cell culture
The human cancer cell lines A549 (lung), HCT116 (colon), MCF7
(breast) and MIAPaCa2 (pancreas) were obtained from the Cancer
Research UK Cell Production Laboratories. The KM cell line was
developed in house from a patient with melanoma. All cells were
maintained in culture medium supplemented with 10% (v/v) foetal
bovine serum (FBS), 2 mM L-glutamine and 1% penicillin/
streptomycin (basal culture medium). All cell lines were incubated
in a humidified atmosphere with 5% CO2 in air at 37 1C, and
discarded when the passage number exceeded 15.
Peripheral-blood mononuclear cells were isolated from whole
blood or from the residue product of leucoreduction of whole
blood from pathologically healthy donors (National Blood Service,
London, UK) using Histopaque-1077 (Sigma Ltd, Dorset, UK). The
mononuclear fraction was harvested and red blood cell contam-
ination removed by incubation in hypotonic ammonium chloride.
Cells were washed in phosphate buffered saline (PBS) and platelet
contamination removed by centrifugation at 200 g for 10 min,
resuspended at a concentration of 1 106 ml1 in RPMI-1640
culture medium containing freshly reconstituted BCG (Danish
strain 1331; Statens Serum Institut, Copenhagen, Denmark)
vaccine at a concentration of 1 105 CFU ml1 (10 mg ml1), and
incubated for 72 h in a humidified atmosphere with 5% CO2 in air
at 37 1C. Peripheral-blood mononuclear cells were removed by
centrifugation at 200 g for 10 min for analysis of immune cell
profile. The exhausted medium was then centrifuged at B16 000 g
for 10 min before storing at 80 1C, and those from BCG-treated
PBMCs were designated as ‘BCG supernatants’ compared with the
‘CONT supernatant’, which were from untreated PBMCs.
Defining immune subsets
Peripheral-blood mononuclear cells were washed twice in wash
buffer (PBS containing 1% (v/v) FBS and 0.09% (v/v) NaN3), and
stained for 30 min at 4 1C with the following antibodies: peridinin
chlorophyll protein anti-CD3, phycoerythrin anti-TCRgd, fluor-
escein isothiocyanate (FITC) anti-CD69 and allophycocyanin-
conjugated anti-CD56 (all from BD Biosciences Ltd, Oxford, UK
and used at 1 : 1000). Matched isotype control antibodies were used
to determine background staining. Cells were washed in wash
buffer and fixed in 4% paraformaldehyde (BD Biosciences) for
20 min at 4 1C. Expressions of the surface markers were analysed
using a BD LSR II with dedicated proprietary software (BD
Biosciences).
Cytokine analysis of supernatants
Peripheral-blood mononuclear cells (1 106) were plated into
96-well plates, and cultured with BCG (1 105 CFU ml1) for up to
72 h. Plates were centrifuged at 200 g for 10 min and supernatants
removed. The concentrations of IFN-g, TNF-a, IL10, IL5, IL4 and
IL2 in these PBMC supernatants were determined by using a
Th1/Th2 cytometric bead array (BD Biosciences) according to
manufacturer’s instructions.
Human leucocyte antigen class I
Exponentially growing cells were reset in fresh culture medium at
2 105 ml1. Following a settling-in period of 24 h, cells were
treated for 48 h with the PBMC supernatants. To study the impact
of inhibiting c-Jun N-terminal kinase (JNK) on HLA1 expression,
10mM of SP600125 (Sigma) was included to the cells with and
without the PBMC supernatants. Cells were harvested (1 105) and
washed twice in wash buffer, and then incubated with anti-HLA1-
FITC antibody (anti-HLA:ABC 1 : 1000; BD Biosciences) for 30 min
at 4 1C. Acquisition of data was performed within 1 h using a
FACSCalibur (BD Biosciences). Ten thousand cells were analysed
for each sample, and the mean fluorescence intensity (MFI) of
HLA1 determined using the program WinMDI v2.9 (http://
facs.scripps.edu/software.html).
To study the role of IFN-g and TNF-a on modulating HLA1
expression on tumours, exponentially growing cells were treated
for 24 h with PBMC supernatants in the presence or absence of
anti-IFN-g (AB-285-NA) and anti-TNF-a (AB-210-NA) (both at
10mg ml1: R&D Systems, Oxford, UK). Normal goat IgG was used
as the isotype control. Cells were harvested and HLA1 expression
determined as described previously.
Cytotoxicity assay
T-cells were isolated from pathologically healthy donor buffy coats
(National Blood Service) using sequential negative cell selection
with magnetic beads coated with anti-CD3, followed by positive
cell isolation using magnetic bead coated with anti-CD8 (Miltenyi
Biotec Ltd, Surrey, UK). CD8þ purities were assessed by flow
cytometry, and only those preparations with purities 490% were
used. Tumour cells pretreated with PBMC supernatants for 48 h
were reset in culture medium at 1 104 per well in a 96-well plate,
and allowed to adhere before adding CD8þ T-cells at an
effector:target ratio of 20 : 1. Maximum lysis was established by
culturing cells with 1% triton-X. After a 24-h incubation period,
cell-free media were removed for assessment of lactate dehydro-
genase (LDH) release using a proprietary assay kit (BioVision
Research Products, Mountain View, CA, USA).
Data were presented as %cytotoxicity, which was calculated
from absorbance values at 590 nm using the following formula:
%Cytotoxicity ¼ Atargetþeffector  ðAtarget þ AeffectorÞ
AtargetþTritonX  Atarget
Immunoblotting analysis
Cells were harvested; total cellular protein was solubilised in lysis
buffer (New England Biolabs, Hitchin, UK) and resolved by Tris-
glycine electrophoresis using a 4–12% bis–tris gradient gel.
Following transfer of proteins to 0.45mm nitrocellulose mem-
branes, blocking was performed in 5% (w/v) non-fat milk in TTBS
(0.5% (v/v) Tween-20 in tris buffered saline (50 mM Tris base with
150 mM NaCl; pH 7.6)). Primary antibody probing was performed
with anti-AKT, anti-phospho AKT, anti-ERK, anti-phospho ERK,
anti-JNK, anti-phospho JNK, anti-p38 MAPK and anti-phospho
p38 MAPK. All primary antibodies were obtained from New
England Biolabs and used at a dilution of 1 : 1000, unless stated
otherwise. Anti-GAPDH was used as a loading control (1 : 2000–
New England Biolabs). Following three washing steps in TTBS,
horseradish peroxidase-conjugated antispecies IgG1 was used as
the secondary antibody (Amersham Biosciences Ltd, Little
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Chalfont, UK). Bands were visualised by the ECL-plus detection
system (Amersham).
RESULTS
BCG alters the activation status of immune cell subsets
Peripheral-blood mononuclear cells harvested from healthy
subjects were exposed to BCG for up to 72 h before assessing the
activation status of each of the key immune effector subsets by
flow cytometry. Activation was indicated by CD69 expression, and
our gating strategy is defined in Figure 1A. Results showed that
BCG was capable of increasing the percentage of CD69 expression
in all the cell types studied, and that the increase was apparent as
early as 6 h. Data for 72 h are shown in Figure 1B. Furthermore, the
effect of BCG on CD69 expression on each of the cell types was
robust and consistent in all five replicates.
BCG stimulates cytokine production
The effect of culturing PBMCs with BCG on a number of Th1/Th2
cytokines was assessed by cytometric bead analysis, and results
showed that BCG generally increased the amount of cytokines
detected in the supernatants. This effect was apparent as early as
6 h, and data for the 72 h time-point is shown in Figure 1C. Results
suggested a Th1-biased effect of BCG; specifically, although there
were significant increases in the majority of the cytokines assessed,
the extents to which IFN-g, TNF-a and IL10 were elevated were
greater than for IL5, IL4 and IL2. For example, at 72 h, although
BCG resulted in significant increases in both IFN-g and IL4
compared with untreated controls, the former was increased to a
concentration of B115 000 pg ml1, while the latter was increased
to B32 pg ml1. Furthermore, the concentrations of these two
cytokines were similar in unstimulated control PBMCs (1.8 vs
1.4 pg ml1, respectively).
BCG supernatant increases HLA1 expression on some
tumour cells
The expression of HLA1 was assessed by flow cytometry using a
proprietary antibody directed against HLA –ABC and presented as
MFIs. Our results confirmed that basal HLA1 expression varied in
the cell lines (Liu et al, 2010). The order of expressions were KM
oA549 oMIAPaCa2 oMCF7 oHCT116 (MFI normalised to
isotype control: 0.91±0.0076; 7.5±0.61; 9.1±0.93; 34±2.7;
41±3.9, respectively). There was little effect on HLA1 expression
of culturing KM and MIAPaCa2 cells with BCG supernatant.
However, in A549, HCT116 and MCF7 cells culturing with BCG
supernatant caused significant increases in HLA1 expressions
(Figure 2A); for example, mean MFI in MCF7 cells treated with
BCG supernatant was 760 vs 290 in CONT-supernatant-treated
cells (Po0.02). For clarity, data were also presented relative to the
CONT supernatants (Figure 2B).
HLA1 expression is associated with cytolytic T-cell function
Allogeneic CD8þ T-cells were harvested from pathologically
normal subjects and admixed with tumour cells pre-exposed to
PBMC supernatants. The extent of cell death was established by
assessing LDH activity in the medium by using a proprietary kit.
Results indicated significant increases in the percentage of
cytotoxicity following treatment with BCG supernatant only in
those tumour cells with increased HLA1 expression (Figure 2C).
For example, cytotoxicity in MCF7 cells was increased from a basal
level of just 1.0±0.42% to 19±3.0 when BCG supernatant was
used (P¼ 0.008).
BCG supernatants alter the expressions of important
signalling molecules
To investigate whether the changes in HLA1 expression and/or
cytotoxic responses could be associated with changes in intracel-
lular signalling pathways, whole cell lysates obtained from the five
cells cultured with supernatants were analysed by immunoblotting.
A broad panel of proteins representing key protagonists in a
number of signalling cascades downstream of receptor tyrosine
kinases was surveyed. The intention was to employ this approach
to identify a signalling protein most likely to trigger the phenotypic
changes. Results highlighted differences in the cellular responses
between the cells exposed to supernatants. In those cell lines where
HLA1 was shown to be unaffected by BCG supernatant, there were
no clear changes to the expressions of the signalling molecules
studied (Figure 3A). However, in those cells where HLA1 was
1000
750
500
250
0
0
150 800
600
400
200
0
B
NK NKT100
50
Ce
ll n
u
m
be
r
Ce
ll n
u
m
be
r
0
250 500
FSC
750 1000
104
100
P = 0.007
P = 0.046
P = 0.045
P = 0.088
IFN IL10 IL5
Cytokine
IL4 IL2TNF
P = 0.034
P = 0.097 P = 0.003
P = 0.245
P = 0.001BCG-treatedUntreated
BCG-treatedUntreated
P = 0.005
75
Pe
rc
e
n
ta
ge
 C
D6
9 
+v
e
50
25
Am
ou
nt
 (p
g m
l–1
)
NKT
Lymphocyte subset
NK B
0
104
103

 

103
102
102
101
101
CD3
100
104
106
105
103
102
101
100
0
100
104103102101
CD56
100 104103102101
CD56
100
SS
C
TC
R

Figure 1 Effect of BCG on the active status of immune cells and cytokine production. Peripheral-blood mononuclear cells harvested from pathologically
normal subjects were exposed to BCG for up to 72 h before assessing the percentage of CD69-expressing cells by nested flow cytometric analyses. The
gating profile (A) allowed for identification of five immune subsets, and the percentage of CD69 positive cells assessed (B). The amounts of six cytokines
produced by PBMCs in response to BCG were also assessed (C). Each data column represents the mean and s.d. of five separate individuals at the 72-h
time-point, except NKT, where n¼ 2 as only 2/5 donors had detectable levels of NKT cells. P-values from paired t-tests.
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affected by BCG supernatants, there were changes seen (Figure 3B).
Generally, there were small changes to protein expressions;
however, the clearest increases were observed in JNK signalling,
which happened to be common to two of the three cell lines
studied (Figure 3B). Significant increases were also seen to the
phospho expressions of AKT in MCF7 and p38 MAPK in A549.
Disrupting JNK signalling affects HLA1 upregulation by
BCG supernatant
To assess the impact of JNK signalling on HLA1 expression, we
cultured HCT116 and MCF7 cells with SP600125, an anthrapyr-
azolone inhibitor of JNK (Bennett et al, 2001), and assessed the
extent to which HLA1 expression was altered by BCG supernatant.
Early results showed that treating cells with SP600125 did not
completely reverse the HLA1-enhancing effect of the BCG super-
natant. However, results showed that culturing cells in the
presence of SP600125 caused a significant reduction in the ability
of BCG supernatant to enhance HLA1 expression in the cells
(Figure 4A–C). For example, an active concentration of SP600125
reduced the increase in HLA1 expression in MCF7 cells caused by
BCG supernatant from 7.4-fold to 5.4-fold (Figure 4B).
Neutralising IFN-c and TNF-a affects HLA1 upregulation
by BCG supernatant
To explore the effects of IFN-g and TNF-a in BCG supernatants on
modulating HLA1 expression on A549, HCT116 and MCF7 cells,
their activities were disrupted by using antibodies against them.
Results showed that these neutralising antibodies significantly
reversed the HLA1-enhancing effects of the BCG supernatant in the
three cell lines tested (Figure 5A). Furthermore, the enhanced
cytotoxicity afforded by T-cells that was associated with increased
HLA1 expression was negated by this co-culture with the
neutralising antibodies (Figure 5B).
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Figure 2 Effect of supernatants on HLA1 expression in tumour cells. Five tumour cell lines were cultured for 24 h with the supernatants derived from
PBMCs treated with BCG (BCG-supernatant), before assessing HLA1 expression on the tumour cells. The basal levels of HLA1 expression expressed as MFI
relative to the isotype control are presented in the text. The magnitudes of these expressions were compared with those on tumours after stimulation with
supernatants from untreated PBMCs (CONT-supernatant). Data were presented as raw MFI (A) or relative to the respective controls (B). The relationship
between HLA1 expression and cytotoxic effect of allogeneic CD8þ T-cells were assessed by measuring LDH activity (C). Effector : target ratios were at
20 : 1 and each data column represented the mean and s.d. of at least three separate experiments. P-values were from paired tests.
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DISCUSSION
This study was undertaken as part of our larger remit to investigate
the role of immunotherapies in an oncological setting, with
particular interest in understanding the value of combining them
with other modalities. These combinations could include agents
that both directly and indirectly contributed to an improved
action. In the current study, we specifically investigated the
immunopotentiating effects of BCG, and explored their direct
effects on PBMCs, as well as the effects that supernatants derived
from these preparations could have on tumour cells directly. In
summary, our results showed that BCG potently increased the
activity of a number of immune subsets, which lead to significant
potentiation of the cytokine output of these cells. Additionally, the
supernatants in which they were found significantly increased
HLA1 expression on a number of tumour cell lines. Increased
immunovisibility was dependent upon these cytokines and
associated with enhanced cytolytic T-cell activity. Moreover, the
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ability of tumour cells to upregulate HLA1 was partially mediated
by JNK signalling.
A large number of malignant diseases are associated with
suppression of cell-mediated immune responses, but humoral
immunity remains unchanged or is increased (Dalgleish and
O’Byrne, 2002). This presents the interesting notion that oncogen-
esis can sabotage cell-mediated immunity by biasing the Th1-/Th2-
response towards a Th2-dominant immune profile that supports
cancer growth (De Monte et al, 2011). We and others have
suggested that adjusting this ‘immune rheostat’ to a Th1-dominant
setting can restore potent cell-mediated immunity, and result in
objective tumour responses (Heriot et al, 2000; Dalgleish and
O’Byrne, 2002). These approaches could include BCG, which is
known to alter the profile of cytokine output of PBMCs
(Alexandroff et al, 1999; Luo et al, 2003). For that reason, in the
first part of our study, we cultured freshly harvested PBMCs from
pathologically normal individuals, and assayed their responses to
BCG vaccine used at a clinically achievable concentration
(1 105 CFU ml1). Our results showed that BCG significantly
increased the percentage of cells expressing the early activation
marker CD69, and that these increases were seen in all the immune
subsets surveyed. Subsequent analysis of the cytokines released
into the supernatants from PBMCs following BCG treatment
revealed higher levels of IFN-g in comparison with IL4, suggestive
of a Th1-predominant response supportive of antitumour action.
Although the specific source of these cytokines was not identified
in the current study, we have previously seen significant increases
in intracellular levels of IFN-g, TNF-a and IL2 in CD3þ CD4þ
cells following stimulation with BCG and other mycobacteria
preparations (data not shown). Nevertheless, what was clear was a
clear and significant increase in the Th1-cytokines IFN-g and
TNF-a that are profoundly associated with the regulation of HLA1
(Seliger et al, 2008), which highlights another facet of BCG that is
exploitable therapeutically.
Manipulating tumour HLA1 expression as a means of potentiat-
ing the efforts of cytotoxic effectors is complex. There appears to
be a fine balance in which levels are kept low to ensure evasion of
CD8þ T-cells surveillance. However, loss of HLA1 opens the door
to innate immune responses involving NK cells, which serve to
clear cells that are devoid of or low in HLA1 (Du and Wang, 2011).
Thus, restoring HLA1 expression in this way could inadvertently
have the opposite effect of protecting cells from therapy by
rendering tumour cells refractory to NK cell-mediated lysis
(Storkus et al, 1991). These considerations need to be made when
manipulating HLA1 expression, but it is worth noting that selective
pressures on tumours results in reductions rather than increases in
HLA1, which suggests that evasion of the adaptive response may be
the more favourable outcome (Cabrera et al, 2003; Aptsiauri et al,
2007). These reductions can be caused by the loss of transcription
and translation elements (Garrido et al, 1993) or epigenetic
modifications that silence regulatory genes (Tomasi et al, 2006).
Losses can also result from dysregulations of cellular signalling
pathways, which are commonly altered in cancer cells, as well as from
reduced responsiveness to cytokines (Rodrı´guez et al, 2007).
Therefore, therapeutic interventions that can counter these oncogenic
transformations and/or restore immunovisibility would be of value.
We have previously reported similar HLA1-modulating actions
of some chemotherapies (Liu et al, 2010), and so adopted similar
models to investigate the effect that the exhausted media from
PBMCs cultured with BCG could have on HLA1 expression in a
panel of tumour cell lines. Results showed HLA1 to be significantly
increased in a number of cell lines, some of which had intrinsically
low starting levels, and that these enhancements were associated
with clear improvements in the cytotoxic actions of allogeneic
CD8þ T-cells. Our results thus support the notion that BCG
supernatants can increase HLA1 expression on tumour cells, and
therefore, indirectly enhance tumour clearance. While it is already
known that BCG can stimulate PBMCs to produce IFN-g (Luo et al,
2003), and that recombinant IFN-g can enhance HLA1 expression
(Seliger et al, 2008), our data unite these two concepts by
highlighting the ability of supernatants from BCG-treated PBMCs
to boost HLA1 expression directly. Furthermore, the basal levels of
HLA1 expressions on tumours do not directly influence their
ability of being upregulated by these BCG supernatants. The
tantalising possibility that other mycobacteria possess similar
HLA1-boosting effects is currently being explored.
We next assessed the impact of BCG supernatants on four
molecules downstream of cytokine receptors, which represented
key components of intracellular signalling involved in the growth
and development in cancer cells (Sebolt-Leopold and English,
2006). Our intention was to identify components that were
common to the cell lines tested and not to fully deconvolute
complex interplay between the cascades. Of particular interest was
JNK, which was altered in two of the three cell lines studied.
Antagonising JNK activity in tumour cells exposed to BCG
supernatant significantly interfered with its ability to increase
HLA1, which supported the important role of JNK signalling and
HLA1 expression in tumour cells. Moreover, the JNK pathway has
a prominent role in regulating HLA1 expression in tumour cells,
whose activity is determined by IFN-g signalling (Bach et al, 1997).
In support of the observations on JNK signalling, we also explored
further the roles of IFN-g and TNF-a in increasing HLA1
expression on tumours. Our results showed that antagonising the
actions of these cytokines by using neutralising antibodies against
them negated the increase in HLA1 expression caused by BCG
supernatant. Moreover, the enhanced cell death associated with
increased HLA1 was also lost (Figure 5). This has been seen
previously in the context of melanoma, where disrupting IFN-g
signalling can adversely affect HLA1 functionality in tumours
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Figure 5 Effect of anti-IFN-g and anti-TNF-a on HLA1 expression.
A549, HCT116 and MCF7 cells were cultured with BCG supernatant in the
presence or absence of neutralising antibodies against IFN-g and TNF-a.
Antagonising these cytokines caused reversal of the increases in HLA1 seen
as a consequence of BCG-supernatant culture (A). Furthermore, culturing
with the neutralising antibodies disrupted the extent of cytotoxicity seen
with admixing with CD8þ T-cells (B). Each data column represents the
mean and s.d. of at least three separate experiments.
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(Rodrı´guez et al, 2007; Respa et al, 2011). Parenthetically, the
melanoma cell line KM that was used in our study was refractory
to BCG supernatant, and moreover, culturing them directly with
active doses of recombinant IFN-g had no effect on HLA1
expression (data not shown). This suggests differences in the
mechanisms of these cytokines in modifying HLA1 that are cell
line dependent. Further work to deconvolute these signalling
pathways is ongoing, and will go someway in helping to identify
drug partners for combination therapies, which may vary and be
patient/tumour specific.
In summary, studies have suggested that the induction of an
effective immune response could assist in the elimination of
tumour. Approaches have included using DC vaccines to stimulate
T-cell responses, and potentiating the cytolytic actions of T-cells
through the use of cytokines (Copier et al, 2011). However, to date,
successes have been limited. In spite of this, one area that has
gained momentum recently is the use of conventional chemother-
apy as immune stimulators. This exploits the multiple mechanisms
of their action and utilises the immune-related effects of some
chemotherapies that support a cell-mediated effect. For this
reason, competent T-cell and NK cell functions are understandable
pre-requisites to maximising the benefits of this approach.
Therefore, individuals with a compromised immune system, or
those possessive of one that is biased towards a Th2-response, may
not benefit as much. For this reason, employing BCG as an
adjuvant to these chemotherapies could be clinically useful for two
reasons; first, by restoring the immune rheostat to an antitumour
setting, and second, by restoring immune visibility of tumours via
the HLA1-enhancing properties. Taken together, these data
support a combination strategy, in which chemotherapy is
supplemented with systemic immune stimulation, and that this
approach would be a powerful tool in cancer therapy.
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